Kane Biotech (TSE:KNE) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Kane Biotech Inc. is set to accelerate the development of its DispersinB® Wound Gel through a collaboration with one of the world’s largest wound care companies, backed by funding and advisory services from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The six-month project aims to create a Proof-of-Concept for the gel, leveraging Kane’s biotech expertise and the financial support of up to $75,000. This partnership is a significant step for Kane Biotech, which specializes in technologies to prevent and remove microbial biofilms and has a diverse portfolio of biotechnologies and products.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.